Roche and Cipla Expand Their 2018 Agreement to Improve Access of Oncology Therapies in India

 Roche and Cipla Expand Their 2018 Agreement to Improve Access of Oncology Therapies in India

Roche and Cipla Expand Their 2018 Agreement to Improve Access of Oncology Therapies in India

Shots:

  • Cipla expands partnership with Roche to improve access to key oncology medicines which include Herclon (trastuzumab), Avastin (bevacizumab) and Ristova (rituximab) in India. Cipla will be responsible for the marketing and distribution of Roche’s key products
  • In Feb’2018, the two companies collaborated for the promotion and distribution of Actemra (tocilizumab) and other products
  •  The collaboration will focus on providing Roche innovations in India while the Roche will keep on collaborating with the relevant stakeholders in the Indian healthcare system to ensure better outcomes for patients

Click here to read full press release/ article | Ref: Cipla | Image: Pharmaworld

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post